论文部分内容阅读
目的 探讨沙美特罗替卡松气雾剂联合有氧运动对慢性阻塞性肺疾病(COPD)稳定期患者血清基质金属蛋白酶组织抑制因子(TIMP - 1)、基质金属蛋白酶9(MMP - 9)水平变化及日常生活能力(ADL)评分的影响.方法 选取2015年1月-2017年1月郑州市第七人民医院92例COPD患者,随机数字表法分组,各46例.对照组予以常规治疗,在此基础上,研究组予以沙美特罗替卡松气雾剂+有氧运动,均连续治疗1个月.观察对比两组肺功能变化[第1秒用力呼气量(FEV1)、第1秒用力呼气量与用力肺活量比值(FEV1/FVC)]情况、血清MMP - 9、TIMP - 1水平变化情况、ADL评分.结果 治疗后研究组FEV1/FVC、FEV1均高于对照组,差异有统计学意义(P ＜ 0.05);治疗后研究组血清MMP - 9、TIMP - 1水平低于对照组,差异有统计学意义(P ＜ 0.05);治疗后研究组ADL评分高于对照组,差异有统计学意义(P ＜ 0.05).结论 沙美特罗替卡松气雾剂联合有氧运动有利于改善COPD稳定期患者肺功能,降低血清MMP - 9、TIMP - 1水平,提高ADL评分.“,”Objective To explore the effects of salmeterol aerosol combined with aerobic exercise on serum TIMP - 1, MMP - 9 levels and ADL score in patients in stable stage of COPD. Methods Totally 92 cases of COPD from January2015 to January 2017 in Zhengzhou NO. 7 People's Hospital were randomly divided into 2 groups(each 46 cases). The control group was given conventional treatment, and on this basis, the study group was given salmeterol aerosol combined with aerobic exercise. Both groups were treated continuously for 1 month. The changes of pulmonary function in the two groups (the forced expiratory volume (FEV1) in the first second, the forced expiratory volume in the first second and the ratio of forced vital capacity (FEV1/FVC)], the changes of serum MMP - 9 and TIMP - 1 levels, and the ADL score were observed and compared. Results After treatment, FEV1 and FEV1/FVC in the study group were higher than those of the control group, and the difference was statistically significant (P ＜ 0.05); the serum MMP - 9, TIMP - 1levels of the study group were lower than those of the control group, and the difference was statistically significant (P ＜0.05); the ADL scores of the study group was higher than that of the control group, the difference was statistically significant(P ＜ 0.05). Conclusion Salmeterol aerosol combined with aerobic exercise can improve the pulmonary function in patients in stable stage of COPD, reduce the serum levels of MMP - 9 and TIMP - 1, and increase the ADL score.